Real-world use of ipilimumab and nivolumab monotherapy or in combination in patients with advanced melanoma: results from a retrospective chart review

被引：0
|
作者：
Tarhini, A. [1 ]
Macahilig, C. [2 ]
Atzinger, C. [3 ]
Gupte-Singh, K. [4 ]
Solem, C. [3 ]
Rao, S. [4 ]
机构：
[1] Univ Pittsburgh, Med Ctr, Div Hematol Oncol, Pittsburgh, PA USA
[2] Med Data Analyt, Res Operat, Parsippany, NJ USA
[3] Pharmerit Int, Global Hlth Econ & Outcomes Res, Bethesda, MD USA
[4] Bristol Myers Squibb, Hlth Econ Outcomes Res, Princeton, NJ USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1250P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
    Serra-Bellver, Patricio
    Versluis, Judith M.
    Oberoi, Honey K.
    Zhou, Cong
    Slattery, Timothy D.
    Khan, Yasir
    Patrinely, James R.
    da Silva, Ines Pires
    Martinez-Vila, C.
    Cook, Natalie
    Graham, Donna M.
    Carlino, Matteo S.
    Menzies, Alexander M.
    Arance, Ana M.
    Johnson, Douglas B.
    Long, Georgina, V
    Pickering, Lisa
    Larkin, James M. G.
    Blank, Christian U.
    Lorigan, Paul
    EUROPEAN JOURNAL OF CANCER, 2022, 176 : 121 - 132
  • [2] Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia
    Takuya Maeda
    Azusa Hiura
    Jiro Uehara
    Rino Toyoshima
    Tomoe Nakagawa
    Koji Yoshino
    European Journal of Dermatology, 2021, 31 : 662 - 664
  • [3] Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia
    Maeda, Takuya
    Hiura, Azusa
    Uehara, Jiro
    Toyoshima, Rino
    Nakagawa, Tomoe
    Yoshino, Koji
    EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (05) : 662 - 664
  • [4] Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma
    Takahashi, Akira
    Namikawa, Kenjiro
    Ogata, Dai
    Nakano, Eiji
    Jinnai, Shunichi
    Nakama, Kenta
    Tsutsui, Keita
    Muto, Yusuke
    Mizuta, Haruki
    Yamazaki, Naoya
    JOURNAL OF DERMATOLOGY, 2020, 47 (11): : 1267 - 1275
  • [5] Real-world Data on advanced Melanoma: First Data from a national, prospective, non-interventional Study of Nivolumab in Combination with Ipilimumab or as Nivolumab Monotherapy (NICO)
    Weichenthal, M.
    Gutzmer, R.
    Eigentler, T.
    Mohr, P.
    Goeppner, D.
    Haferkamp, S.
    Herber, M.
    Herbst, R.
    Meier, F.
    Meiss, F.
    Pfoehler, C.
    Schneider, S. W.
    Terheyden, P.
    Ulrich, J.
    Utikal, J.
    Weishaupt, C.
    Welzel, J.
    Schadendorf, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 5 - 6
  • [6] Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
    van Zeijl, M. C. T.
    Wouters, M. W. J. M.
    van den Eertwegh, A. J. M.
    de Wreede, L. C.
    Aarts, M. J. B.
    van Akkooi, A. C. J.
    Van den Berkmortel, F. W. P. J.
    de Groot, J. W.
    Boers-Sonderen, M. J.
    van der Hoeven, J. J. M.
    Hospers, G. A. P.
    Kapiteijn, E.
    Piersma, D.
    van Rijn, R. S.
    Suijkerbuijk, K. P. M.
    Ten Tije, A. J.
    Van der Veldt, A. A. M.
    Vreugdenhil, G.
    Haanen, J. B. A. G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] HEALTHCARE COST COMPARISON ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
    Potluri, R.
    Bhandari, H.
    Ranjan, S.
    Moshyk, A.
    Kotapati, S.
    VALUE IN HEALTH, 2019, 22 : S72 - S73
  • [8] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Ravi Potluri
    Sandip Ranjan
    Hitesh Bhandari
    Helen Johnson
    Andriy Moshyk
    Srividya Kotapati
    Experimental Hematology & Oncology, 8
  • [9] Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
    Potluri, Ravi
    Ranjan, Sandip
    Bhandari, Hitesh
    Johnson, Helen
    Moshyk, Andriy
    Kotapati, Srividya
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (1)
  • [10] Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038
    Ribas, Antoni
    Martin-Algarra, Salvador
    Bhatia, Shailender
    Hwu, Wen-Jen
    Slingluff, Craig L.
    Sharfman, William H.
    Hodi, F. Stephen
    Urba, Walter J.
    Luke, Jason J.
    Haanen, John B.
    Callahan, Margaret K.
    Wolchok, Jedd D.
    Chasalow, Scott D.
    Ross-Macdonald, Petra
    Young, Tina C.
    Qureshi, Anila
    Horak, Christine E.
    CANCER RESEARCH, 2017, 77
12345